If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



EC Launches Inquiry Into Pharma Industry

January 21, 2008 | A version of this story appeared in Volume 86, Issue 3

The European Commission has launched what it calls a sector inquiry into competition in the pharmaceuticals industry, sending teams of inspectors on surprise visits to the headquarters of several drug companies around Europe. "We have launched this inquiry because pharmaceuticals markets are not working as well as they might," explained Neelie Kroes, commissioner for competition policy, at a press conference in Brussels. Patent protection has never been stronger, she said, "but the number of new pharmaceuticals coming to market is declining." Moreover, "generic manufacturers are not jumping into the markets as quickly as we would expect." The inquiry will examine whether agreements between pharmaceutical companies, such as patent dispute settlements, infringe antitrust regulations and if companies have created artificial barriers to entry through the misuse of patent rights and vexatious litigation. The EC concedes that tighter regulations adopted in Europe since 1995 may have had an impact on the number of new drugs brought to market, but it clearly doesn't believe that regulations alone fully explain the decline in introductions. Kroes plans to issue an interim report this fall and a final report in the spring of 2009.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.